Damora Therapeutics (DMRA) Financials: Revenue & Earnings
DMRA$21.65-0.31 -1.41%
$1.34B
Market Cap
-0.17
P/E
—
Forward P/E
70
Score
Damora Therapeutics (DMRA) Financials: Revenue & Earnings
DMRA price $21.65 -0.31 -1.41%
- Ticker
- DMRA
- Price
- $21.65
- Change
- -0.31 -1.41%
- Market cap ?
- $1.34B
- P/E ?
- -0.17
- Dividend yield ?
- 0.00%
- Beta ?
- 1.44
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 70
- Value
- 58
- Quality
- 52
- Growth
- 100
Stocklytics score rationale: value 58, quality 52, growth 100.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address…
Fair value
DMRA fair value Not meaningful. Price $21.65.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | -0.48 | — | — |
| 2026-08-11 | -0.39 | -0.41 | — | — |
| 2026-05-12 | -0.62 | -0.21 | — | — |
| 2026-03-18 | -3.24 | -0.14 | — | — |
| 2025-11-06 | -2.36 | -0.10 | — | — |
| 2025-08-05 | -2.60 | — | — | — |
| 2025-05-08 | -1.92 | — | — | — |
| 2025-03-19 | -5.22 | -2.97 | — | — |
| 2024-11-01 | -3.39 | -3.70 | — | — |
| 2024-08-12 | -4.92 | -6.04 | — | — |
| 2024-04-29 | -5.05 | -10.25 | — | — |
| 2024-03-08 | -5.96 | -8.75 | — | — |
| 2023-03-09 | -13.75 | -14.25 | — | — |
| 2022-02-18 | -13.25 | -14.00 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Jarrett Jennifer | Buy | 12.50K | $20.23 | 252.88K |
| 2026-08-12 | Cheng Andrew | Buy | 30.35K | $31.00 | 940.85K |
| 2026-08-12 | Cheng Andrew | Other | 0 | — | — |
| 2026-07-06 | Winslow Garrett | Sell | 245 | $29.98 | 7.35K |
| 2026-07-03 | Winslow Garrett | Buy | 680 | — | — |
| 2026-07-03 | Winslow Garrett | Sell | 680 | — | — |
| 2026-05-01 | Burkavage Brian | Other | 312.54K | $32.00 | 10.00M |
| 2026-03-30 | Jarrett Jennifer | Buy | 1.50M | $25.50 | 38.25M |
| 2026-03-30 | Jarrett Jennifer | Buy | 500.00K | — | — |
| 2026-03-30 | Jarrett Jennifer | Other | 0 | — | — |
| 2026-03-23 | Winslow Garrett | Buy | 250.00K | $23.05 | 5.76M |
| 2026-03-23 | Turtle Cameron | Buy | 37.31K | $23.05 | 860.06K |
| 2026-03-23 | Landsittel Michael | Buy | 37.31K | $23.05 | 860.06K |
| 2026-03-23 | Fairmount Funds Management LLC | Buy | 37.31K | $23.05 | 860.06K |
| 2026-03-23 | CAIN CHRISTOPHER W. | Buy | 37.31K | $23.05 | 860.06K |
| 2026-03-23 | Bruno Julianne | Buy | 37.31K | $23.05 | 860.06K |
| 2026-03-23 | Turtle Cameron | Other | 0 | — | — |
| 2026-03-23 | Landsittel Michael | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 103, holders +39 vs prior quarter. Ownership 105.64%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 9.23M | 187.50K | +2.07% | 240.15M |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 8.71M | 0 | 0.00% | 226.63M |
| AVORO CAPITAL ADVISORS LLC | 3.78M | 0 | 0.00% | 98.40M |
| VENROCK ADVISER, LLC | 3.60M | 0 | 0.00% | 93.73M |
| BLACKROCK, INC. | 3.16M | 2.94M | +1321.56% | 82.25M |
| FCPM III SERVICES B.V. | 2.44M | 0 | 0.00% | 63.49M |
| RA CAPITAL MANAGEMENT, L.P. | 2.40M | 392 | +0.02% | 62.42M |
| VIKING GLOBAL INVESTORS LP | 2.31M | 0 | 0.00% | 60.11M |
| JUPITER TOPCO LLC | 2.28M | 2.28M | New | 59.28M |
| REMEDIUM CAPITAL PARTNERS, LLC | 2.05M | 0 | 0.00% | 53.20M |
| COMMODORE CAPITAL LP | 1.94M | 0 | 0.00% | 50.43M |
| JPMORGAN CHASE & CO | 2.06M | 2.06M | New | 49.85M |
| BRAIDWELL LP | 1.62M | 725.53K | +81.08% | 42.15M |
| BELLEVUE GROUP AG | 1.62M | -679.15K | -29.55% | 42.11M |
| STATE STREET CORP | 1.55M | 1.36M | +740.30% | 40.20M |
| A16Z CAPITAL MANAGEMENT, L.L.C. | 1.24M | 0 | 0.00% | 32.15M |
| BALYASNY ASSET MANAGEMENT L.P. | 1.23M | -218.87K | -15.12% | 31.97M |
| PERCEPTIVE ADVISORS LLC | 1.22M | 0 | 0.00% | 31.81M |
| WELLINGTON MANAGEMENT GROUP LLP | 1.06M | 0 | 0.00% | 27.52M |
| BLACKSTONE INC. | 1.00M | 499.45K | +99.19% | 26.09M |
| CORMORANT ASSET MANAGEMENT, LP | 1.00M | -525.00K | -34.43% | 26.01M |
| GEODE CAPITAL MANAGEMENT, LLC | 965.36K | 724.24K | +300.36% | 25.11M |
| SIREN, L.L.C. | 900.00K | 0 | 0.00% | 23.41M |
| UBS GROUP AG | 840.29K | 679.88K | +423.82% | 21.86M |
| VESTAL POINT CAPITAL, LP | 575.00K | -25.00K | -4.17% | 14.96M |
Earnings and financials
Damora Therapeutics, Inc. (DMRA) trades at $21.65, with a market cap of $1.34B and a trailing P/E of -0.17. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn